<i>HLADQA1*05</i> genotype predicts anti‐drug antibody formation and loss of response during infliximab therapy for inflammatory bowel disease

Abstract

HLADQA1*05 is independently associated with a high risk of infliximab antibody formation in addition to infliximab loss of response and treatment discontinuation. There may be a role for genotype-guided application of combination therapy in IBD.